TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER

被引：0
|
作者：
Heng, Sharon [1 ]
Pokharel, Khageshwor [1 ]
Gilbar, Peter [1 ]
Tannock, Margot [1 ]
机构：
[1] Toowoomba Base Hosp, Dept Med Oncol, Toowoomba, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
321
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [1] Metastatic breast cancer: A regional audit of HER2 testing and trastuzumab access.
    Scullin, P.
    Drake, A. T.
    Coyle, V. M.
    McAleer, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 324S - 324S
  • [2] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [3] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    Lluch-Gomez, J.
    Nunez-Alvarez, V.
    de la Torre-Hita, C.
    Bernal-Gomez, M.
    Campini-Bermejo, A.
    Perdomo-Zaldivar, E.
    Rodriguez-Perez, L.
    Calvete-Candenas, J.
    Martinez-Bautista, M. J.
    Benitez-Rodriguez, E.
    Baena-Canada, J. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [4] POPULATION BASED OUTCOME OF HER2 POSITIVE EARLY BREAST CANCER IN TRASTUZUMAB ERA
    Matos, E.
    Kuhar, C. Grasic
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 113
  • [5] Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuaki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 723 - 724
  • [6] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
  • [7] PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer
    Earl, H. M.
    Cameron, D. A.
    Miles, D.
    Wardley, A. M.
    Ogburn, E. R. M.
    Vallier, A-L
    Loi, S.
    Higgins, H. B.
    Hiller, L.
    Dunn, J. A.
    CANCER RESEARCH, 2012, 72
  • [8] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [9] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [10] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
12345